Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib with or without Atezolizumab in BRCA-Mutated Non-HER2-Positive Breast Cancer
NCT02849496Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2017
- Primary completion
- Jun 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in breast cancer, sponsored by National Cancer Institute. Started Mar 2017; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02849496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02849496.